Search

Your search keyword '"Fraticelli, P."' showing total 10 results
Start Over Author "Fraticelli, P." Publisher bmj
10 results on '"Fraticelli, P."'

1. POS1214 COVID-19 VACCINATION RATE AND SAFETY PROFILE IN PATIENTS AFFECTED BY MIXED CRYOGLOBULINEMIC VASCULITIS.

Author

Vacchi, C., primary, Testoni, S., additional, Visentini, M., additional, Zani, R., additional, Lauletta, G., additional, Gragnani, L., additional, Filippini, D. A., additional, Mazzaro, C., additional, Fraticelli, P., additional, Quartuccio, L., additional, Padoan, R., additional, Castelnovo, L., additional, Zignego, A. L., additional, Ferri, C., additional, Hoxha, A., additional, Salvarani, C., additional, Monti, G., additional, Galli, M., additional, and Sebastiani, M., additional

Published
2022
Full Text
View/download PDF

2. OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS

Author

Bettiol, A., primary, Urban, M. L., additional, Alberici, F., additional, Agostini, C., additional, Baldini, C., additional, Bozzolo, E., additional, Cameli, P., additional, Crimi, N., additional, Del Giacco, S., additional, Egan, A., additional, Espigol-Frigole, G., additional, Felicetti, M., additional, Folci, M., additional, Fraticelli, P., additional, Govoni, M., additional, Kernder, A., additional, Lombardi, C., additional, Lopalco, G., additional, Lunardi, C., additional, Mohammad, A. J., additional, Moosig, F., additional, Negrini, S., additional, Neumann, T., additional, Novikov, P., additional, Paolazzi, G., additional, Parronchi, P., additional, Quartuccio, L., additional, Racanelli, V., additional, Salvarani, C., additional, Samson, M., additional, Schroeder, J., additional, Sciascia, S., additional, Sinico, R. A., additional, Terrier, B., additional, Toniati, P., additional, Prisco, D., additional, Vaglio, A., additional, and Emmi, G., additional

Published
2020
Full Text
View/download PDF

5. OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins

Author

Quartuccio, L., primary, Corazza, L., additional, Ramos-Casals, M., additional, Retamozo, S., additional, Ragab, G.M., additional, Ferraccioli, G., additional, Gremese, E., additional, Tzioufas, A., additional, Voulgarelis, M., additional, Vassilopoulos, D., additional, Koutsianas, C., additional, Scarpato, S., additional, Salvarani, C., additional, Guillevin, L., additional, Terrier, B., additional, Cacoub, P., additional, Saccardo, F., additional, Gabrielli, A., additional, Fraticelli, P., additional, Tomsic, M., additional, Tavoni, A., additional, Nishimoto, N., additional, Filippini, D., additional, Scaini, P., additional, Zignego, A.L., additional, Ferri, C., additional, Sansonno, D., additional, Monti, G., additional, Pietrogrande, M., additional, Galli, M., additional, Bombardieri, S., additional, and De Vita, S., additional

Published
2015
Full Text
View/download PDF

6. OP0228 Rituximab Monotherapy of Severe Hcv-Related Cryoglobulinemic Vasculitis for More than 2 Years: Follow-Up of A Randomized Controlled Multicentre Study

Author

Quartuccio, L., primary, Zuliani, F., additional, Corazza, L., additional, Scaini, P., additional, Zani, R., additional, Lenzi, M., additional, Tavoni, A., additional, Sebastiani, M., additional, Baldovino, S., additional, Urraro, T., additional, Saccardo, F., additional, Sbreglia, C., additional, Mazzaro, C., additional, Pioltelli, P., additional, Fraticelli, P., additional, Filippini, D., additional, Gabrielli, A., additional, Perrella, O., additional, Scarpato, S., additional, Roccatello, D., additional, Zignego, A.L., additional, Ferri, C., additional, Bombardieri, S., additional, Pietrogrande, M., additional, Galli, M., additional, Monti, G., additional, and De Vita, S., additional

Published
2014
Full Text
View/download PDF

7. SAT0175 Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study

Author

De Vita, S., primary, Quartuccio, L., additional, Isola, M., additional, Corazza, L., additional, Ramos-Casals, M., additional, Retamozo, S., additional, Ragab, G., additional, Zoheir, N., additional, El Menyawi, M. M., additional, Salem, M., additional, Sansonno, D., additional, Conteduca, V., additional, Ferraccioli, G., additional, Gremese, E., additional, Tzioufas, A., additional, Voulgarelis, M., additional, Vassilopoulos, D., additional, Koutsianas, C., additional, Zignego, A. L., additional, Urraro, T., additional, Pipitone, N., additional, Salvarani, C., additional, Ghinoi, A., additional, Guillevin, L., additional, Terrier, B., additional, Cacoub, P., additional, Filippini, D., additional, Saccardo, F., additional, Gabrielli, A., additional, Fraticelli, P., additional, Tomsic, M., additional, Ferri, C., additional, Sebastiani, M., additional, Tavoni, A., additional, Catarsi, E., additional, Mazzaro, C., additional, Pioltelli, P., additional, Nishimoto, N., additional, Scaini, P., additional, Monti, G., additional, Pietrogrande, M., additional, Galli, M., additional, and Bombardieri, S., additional

Published
2013
Full Text
View/download PDF

8. SAT0213 Low-Dose Imatinib in the Treatment of Scleroderma Pulmonary Involvement: Results of a Phase II Pilot Study.

Author

Fraticelli, P., primary, Pomponio, G., additional, Gabrielli, B., additional, Riboldi, P., additional, Ferraccioli, G., additional, Giacomelli, R., additional, Del Papa, N., additional, Bombardieri, S., additional, Malorni, W., additional, Gerli, R., additional, Lunardi, C., additional, Faggioli, P., additional, Corvetta, A., additional, Valentini, G., additional, and Gabrielli, A., additional

Published
2013
Full Text
View/download PDF

9. Preliminary classification criteria for the cryoglobulinaemic vasculitis

Author

De Vita, S., primary, Soldano, F., additional, Isola, M., additional, Monti, G., additional, Gabrielli, A., additional, Tzioufas, A., additional, Ferri, C., additional, Ferraccioli, G. F., additional, Quartuccio, L., additional, Corazza, L., additional, De Marchi, G., additional, Casals, M. R., additional, Voulgarelis, M., additional, Lenzi, M., additional, Saccardo, F., additional, Fraticelli, P., additional, Mascia, M. T., additional, Sansonno, D., additional, Cacoub, P., additional, Tomsic, M., additional, Tavoni, A., additional, Pietrogrande, M., additional, Zignego, A. L., additional, Scarpato, S., additional, Mazzaro, C., additional, Pioltelli, P., additional, Steinfeld, S., additional, Lamprecht, P., additional, Bombardieri, S., additional, and Galli, M., additional

Published
2011
Full Text
View/download PDF

10. Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.

Author

Molina B, Padoan R, Urban ML, Novikov P, Caminati M, Taillé C, Néel A, Bouillet L, Fraticelli P, Schleinitz N, Christides C, Moi L, Godeau B, Knight A, Schroeder JW, Marchand-Adam S, Gil H, Cottin V, Durel CA, Gelain E, Lerais B, Ruivard M, Groh M, Samson M, Moroni L, Thiel J, Kernder A, Cohen Tervaert JW, Costanzo G, Folci M, Rizzello S, Cohen P, Emmi G, and Terrier B

Subjects
Humans, Retrospective Studies, Prednisone therapeutic use, Treatment Outcome, Recurrence, Granulomatosis with Polyangiitis complications, Granulomatosis with Polyangiitis drug therapy, Granulomatosis with Polyangiitis diagnosis, Churg-Strauss Syndrome complications, Churg-Strauss Syndrome drug therapy, Asthma drug therapy, Asthma complications, Eosinophilia drug therapy, Eosinophilia complications
Abstract

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is often associated with glucocorticoid-dependent asthma and/or ear, nose and throat (ENT) manifestations. When immunosuppressants and/or mepolizumab are ineffective, dupilumab could be an option. We describe the safety and efficacy of off-label use of dupilumab in relapsing and/or refractory EGPA., Patients and Methods: We conducted an observational multicentre study of EGPA patients treated with dupilumab. Complete response was defined by Birmingham Vasculitis Activity Score (BVAS)=0 and prednisone dose ≤4 mg/day, and partial response by BVAS=0 and prednisone dose >4 mg/day. Eosinophilia was defined as an eosinophil count >500/mm 3 ., Results: Fifty-one patients were included. The primary indication for dupilumab was disabling ENT symptoms in 92%. After a median follow-up of 13.1 months, 18 patients (35%) reported adverse events (AEs), including two serious AEs. Eosinophilia was reported in 34 patients (67%), with a peak of 2195/mm3 (IQR 1268-4501) occurring at 13 weeks (IQR 4-36) and was associated with relapse in 41%. Twenty-one patients (41%) achieved a complete response and 12 (24%) a partial response. Sixteen (31%) patients experienced an EGPA relapse while on dupilumab, which was associated with blood eosinophilia in 14/16 (88%) patients. The median eosinophil count at the start of dupilumab was significantly lower in relapsers than in non-relapsers, as was the median time between stopping anti-IL-5/IL-5R and switching to dupilumab., Conclusion: These results suggest that dupilumab may be effective in treating patients with EGPA-related ENT manifestations. However, EGPA flares occurred in one-third of patients and were preceded by eosinophilia in 88%, suggesting that caution is required., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results